Verdant Technology CORP Form 10-Q November 17, 2008

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

ü

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934

For the quarterly period ended: September 30, 2005

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934

For the transition period from: ______ to _____

Commission File Number: 000-50993

Verdant Technology Corporation

(Exact name of registrant as specified in its charter)

Delaware

20-1680252 (I.R.S. Employer Identification No.)

(State or other jurisdiction of incorporation or organization)

Two Allen Center, 1200 Smith Street, Suite 1600, Houston, Texas 77002

(Address of Principal Executive Office) (Zip Code)

(713) 546-9000

(*Registrant* s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

> Yes ü No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Securities Exchange Act of 1934.

Large accelerated filer Accelerated filer Non-accelerated filer (Do not check if a Smaller reporting company ü smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Yes ü No

The number of shares outstanding of Common Stock, \$0.001 par value at November 17, 2008 was 67,502,887.

DOCUMENTS INCORPORATED BY REFERENCE

None

Exchange Act of 1934).

TABLE OF CONTENTS

Ι	Page
Definitions	
1	
Forward-Looking Statements	
1	
PART I FINANCIAL INFORMATION	
Item 1. Financial Statements.	
2	
Balance Sheets	
3	
Statements Of Operations (Unaudited)	
4	
Statements Of Shareholders' Deficiency	
5	
Statements Of Cash Flow (Unaudited)	
<u>6</u>	
Notes to the Financial Statements	
2	
Item 2. Management s Discussion And Analysis Of Financial Condition And Results Of Operations.	
<u>21</u>	
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	
28	
Item 4T. Controls And Procedures.	

<u>29</u>
PART II OTHER INFORMATION
Item 1. Legal Proceedings.
<u>31</u>
Item 1A. Risk Factors.
<u>31</u>
Item 2. Unregistered Sales Of Equity Securities And Use Of Proceeds
<u>36</u>
Item 3. Defaults Upon Senior Securities.
<u>36</u>
Item 4. Submission Of Matters To A Vote Of Security Holders.
<u>36</u>
Item 5. Other Information.
<u>36</u>
Item 6. Exhibits, Financial Statement Schedules.
<u>37</u>
Signatures
<u>39</u>
Certifications
Exhibit 31 Management certification
Exhibit 32 Sarbanes-Oxley Act

Definitions

Acronyms and defined terms used in this text include the following:

APB

Accounting Principles Board

ARB

Accounting Review Board

Aureus

Aureus, LLC, a Florida limited liability company (formerly Packet Solutions LLC)

EITF

Emerging Issues Task Force

EnviroTank

EnviroTank International, LLC, a Louisiana limited liability company and a wholly owned subsidiary (as of May 18, 2006)

EnviroTank

Technology

A crude oil recovery unit/tank cleaning system, designed to deal with the problem of sludge buildup on the bottom of crude oil storage tanks.

FASB

Financial Accounting Standards Board

FSP

FASB Staff Position

JSW

Jewett, Schwartz, Wolfe & Associates

Legkow Technology

A concept utilizing surfactants and emulsions in the treatment and processing of crude oil, waste oils and oil slops

Q3-2005

The three months ended September 30, 2005

QTD2005

The nine months ended September 30, 2005

SAB

Staff Accounting Bulletin

SEC

Securities Exchange Commission

SFAS or FAS

Statement of Financial Accounting Standards

SynChem

SynChem Technologies, LLC, a Florida limited liability company, licensors of the V003 Technology and a wholly owned subsidiary (as of June 16, 2006)

V003 Technology

A 100% biodegradable, non-toxic, non-corrosive, proprietary compound that removes paraffin and asphaltene blockage at the well site

Verdant, VTC or

Company

Verdant Technology Corporation, Delaware corporation

Verdant, Inc.

Verdant, Inc. an affiliate through common ownership and directors

Forward-Looking Statements

Certain sections of this Quarterly Report discuss matters that are not historical facts, but expressions of management s expectations, estimates, projections and assumptions, are forward-looking statements. Words such as expects, intends, anticipates, plans, believes, scheduled, estimates and variations of these words and similar expressions are intendentify forward-looking statements, which include but are not limited to projections of revenues, plans, projections, earnings, product performance, cash flows, contracts, potential market, commercial viability of our technology, production and investment returns. These statements are not guarantees of future performance and involve certain

risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors, including, without limitation:

General U.S. and international political and economic conditions;

Changing priorities in the regulatory environment;

.

.

.

The ability of the Company to secure contracts for its products and services;

The ability to protect our proprietary technology; and

The ability to raise sufficient capital to successfully commercialize our technology.

All forward-looking statements speak only as of the date of this report. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company s behalf are qualified by the cautionary statements in this section. The Company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

1

PART I FINANCIAL INFORMATION

General

The accompanying condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flow, and stockholders deficit in conformity with generally accepted accounting principles in the United States of America. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements included in the Company s annual report on Form 10-KSB for the year ended December 31, 2004. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the quarter ended September 30, 2005 are not necessarily indicative of the results that can be expected for the year ended December 31, 2004 or December 31, 2008.

2

ITEM 1.

FINANCIAL STATEMENTS.

VERDANT TECHNOLOGY CORPORATION

(FKA HeartSTAT Technology, Inc.)

BALANCE SHEETS

<u>ASSETS</u>	September 30, 2005 (Unaudited)			December 31, 2004 (Audited)		
CURRENT ASSETS Cash Prepaid Expenses	\$		\$	1,517		
TOTAL CURRENT ASSETS				1,517		
PROPERTY AND EQUIPMENT, NET						
TOTAL ASSETS	\$		\$	1,517		
LIABILITIES AND SHAREHOLDERS' DEFICIENCY						
CURRENT LIABILITIES						
Accounts Payable and Accrued Expenses	\$	60,518	\$	10,954		
Accrued Interest - Related Parties		21,359		8,815		
Other Payables - Related Parties		23,235		7,500		
TOTAL CURRENT LIABILITIES		105,112		27,269		
LONG TERM NOTES PAYABLE - RELATED PARTIES		209,066		209,066		
TOTAL LIABILITIES		314,178		236,335		
COMMITMENTS AND CONTINGENCIES						
SHAREHOLDERS' DEFICIENCY						
Common Stock, \$.001 par value:						
Authorized 80,000,000 shares; issued and outstanding,						
48,402,887 shares (2005) and (2004)		48,403		48,403		

Additional Paid In Capital		
Accumulated Deficit	(362,581)	(283,221)
TOTAL SHAREHOLDERS' DEFICIENCY	(314,178)	(234,818)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIENCY	\$ \$	1,517

The accompanying notes are an integral part of these financial statements

3

VERDANT TECHNOLOGY CORPORATION

(FKA HeartSTAT Technology, Inc.)

STATEMENTS of OPERATIONS (Unaudited)

	Three Months Ended September 30,			Nine Months Ended September 30,				
	2005		2004		2005		2004	
REVENUES	\$	\$		\$		\$		
COST OF SALES								
GROSS PROFIT								
OPERATING EXPENSES								
General and Administrative	4,549		24,376		13,604		41,033	
Consulting R&D Fees			15,000				35,000	
Corporate Management Fees	15,000		15,000		45,000		30,000	
Legal and Professional Fees	15,467		4,434		20,756		11,114	
TOTAL OPERATING EXPENSES	35,016		58,810		79,360		117,147	
LOSS FROM OPERATIONS	(35,016)		(58,810)		(79,360)		(117,147)	
OTHER EXPENSES (INCOME)								
NET LOSS	\$ (35,016)	\$	(58,810)	\$	(79,360)	\$	(117,147)	
Basic and Fully Diluted Net Loss Per Share	\$ (0.00)	\$	(0.00)	\$	(0.00)	\$	(0.00)	
Weighted Average Shares Outstanding	48,402,887		48,402,887		48,402,887		37,585,369	

The accompanying notes are an integral part of these financial statements

VERDANT TECHNOLOGY CORPORATION

(FKA HeartSTAT Technology, Inc.)

STATEMENTS of SHAREHOLDERS' DEFICIENCY

For the Nine Months Ended September 30, 2005 and For the Year Ended December 31, 2004

	Common Shares	Common Stock	Additional Paid In Capital	 umulated Deficit	Total Shareholders' Deficiency		
Balances, December 31, 2003	10,402,887	\$ 10,403	\$	\$ (52,403)	\$	(42,000)	
Common stock transactions: Shares issued for acquisition of goodwill	38,000,000	38,000				38,000	
Net loss for Q1 2004 Net loss for				(17,263)		(17,263)	